US StockDetailed Quotes

Provided by Tiger Trade Technology Pte. Ltd.

Militia Long/Short Equity ETF

39.15

+0.53491.39%

Volume:41.80K

Turnover:1.64M

Market Cap:357.05M

PE:- -

High:39.27

Open:38.72

Low:38.72

Close:38.62

52wk High:39.80

52wk Low:30.66

Shares:9.12M

Float Shares:9.12M

Volume Ratio:1.41

T/O Rate:0.46%

Dividend:- -

Dividend Rate:- -

ROE:--

ROA:--

PB:--

PE(LYR):- -

Loading ...

Overview Company News Filings

Concept

no data

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

AbbVie announces Phase 3 Cervino study met dual primary endpoints of ORR, PFS

Press Release: CStone 2026 Interim Results: Accelerating Pipeline 2.0 Execution and Sustained Global Commercial Momentum

Press Release: CStone 2026 Interim Results: Accelerating Pipeline 2.0 Execution and Sustained Global Commercial Momentum

Press Release: Harbour BioMed Reports 2026 Interim Results: Three Integrated Growth Engines Accelerate Execution of Its Platform-Based Strategy

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigerplaytime.com/stock/ORR"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"ORR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORR\",,,,,undefined,":{"symbol":"ORR","market":"US","secType":"STK","nameCN":"Militia Long/Short Equity ETF","latestPrice":39.15,"timestamp":1788462831101,"preClose":38.6151,"halted":0,"volume":41799,"delay":0,"changeRate":0.013852094128980643,"floatShares":9120000,"shares":9120000,"eps":0,"marketStatus":"Trading","change":0.5349,"latestTime":"09-03 15:22:27 EDT","open":38.72,"high":39.27,"low":38.72,"amount":1635330.8675159998,"amplitude":0.014243,"askPrice":39.26,"askSize":500,"bidPrice":39.08,"bidSize":600,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"Post-Mkt","tradingStatus":3,"beginTime":1788465600000},"marketStatusCode":2,"adr":0,"exchange":"NASDAQ","adjPreClose":38.6151,"sharesOutstanding":12900000,"nav":38.79,"aum":353764800,"bidAskSpread":0,"postHourTrading":{"tag":"盘后","latestPrice":38.61,"preClose":38.6151,"latestTime":"19:30 EDT","volume":12,"amount":463.3506,"timestamp":1788391805422,"change":-0.0051,"changeRate":-0.000132,"amplitude":0},"volumeRatio":1.408388,"impliedVol":0.1415,"impliedVolPercentile":0.4819},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ORR\",,,,,undefined,":{"symbol":"ORR","floatShares":9120000,"roa":"--","roe":"--","lyrEps":0,"volumeRatio":1.408388,"shares":9120000,"dividePrice":0,"high":39.27,"amplitude":0.014243,"preClose":38.6151,"low":38.72,"week52Low":30.655,"pbRate":"--","week52High":39.8,"institutionHeld":0,"latestPrice":39.15,"committee":0.090909,"eps":0,"divideRate":0,"volume":41799,"delay":0,"ttmEps":0,"open":38.72,"prevYearClose":34.16,"prevWeekClose":38.9187,"prevMonthClose":38.77,"prevQuarterClose":36.32,"fiveDayClose":38.8951,"twentyDayClose":39.52,"sixtyDayClose":35.545},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ORR\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ORR\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ORR\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ORR\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2664587723","title":"AbbVie announces Phase 3 Cervino study met dual primary endpoints of ORR, PFS","url":"https://stock-news.laohu8.com/highlight/detail?id=2664587723","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2664587723?lang=en_us&edition=fundamental","pubTime":"2026-09-03 21:25","pubTimestamp":1788441947,"startTime":"0","endTime":"0","summary":"AbbVie (ABBV) announced positive topline results from the Phase 3 Cervino study evaluating etentamig, an investigational BCMA x CD3 bispecific T-ce...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/abbvie-announces-phase-3-cervino-study-met-dual-primary-endpoints-of-orr-pfs-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/abbvie-announces-phase-3-cervino-study-met-dual-primary-endpoints-of-orr-pfs-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["IE00BJJMRZ35.SGD","LU0203347892.USD","LU0417517546.SGD","IE000WAW04H5.SGD","LU0472753341.HKD","LU0795875169.SGD","IXJ","XLV","SG9999011175.SGD","ORR","GLAM","IE00BLSP4239.USD","LU0320765646.SGD","BK4585","PPH","LU1057294990.SGD","MEDX","FHLC","LU0868494617.USD","LU2089284900.SGD","LU2129689431.USD","LU1585245621.USD","VHT","ABBV","LU0256863811.USD","LU1989772840.SGD","LU2237443465.HKD","FTXH","LU0820561909.HKD","RXL","IE000F7OJYX1.SGD","LU1496350171.SGD","IE0004445239.USD","LU0124676726.USD","LU0942090050.USD","LU1929549753.HKD","LU0965509283.SGD","LU0912757837.SGD","LU0057025933.USD","TRUH","JDOC","LU1093756325.SGD","BK4550","BK4559","LU2357627491.SGD","LU0882574055.USD","AGNG","LU1244550494.USD","PJP","IYH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2663600336","title":"Press Release: CStone 2026 Interim Results: Accelerating Pipeline 2.0 Execution and Sustained Global Commercial Momentum","url":"https://stock-news.laohu8.com/highlight/detail?id=2663600336","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2663600336?lang=en_us&edition=fundamental","pubTime":"2026-08-31 20:23","pubTimestamp":1788178980,"startTime":"0","endTime":"0","summary":"CS2009 Achieved Key Clinical Validations for Efficacy and SafetyAs of August 2026, updated data further confirmed the favorable safety profile of CS2009 and demonstrated strengthened efficacy across multiple key cohorts compared with the data presented at ASCO in May 2026. With expanded patient enrollment and longer follow-up, improvements were observed in both the objective response rate  and duration of response :Compelling monotherapy efficacy in first-line non-small cell lung cancer -- At the 30 mg/kg dose level, CS2009 achieved an ORR of 100% and a disease. control rate  of 100% in patients with PD-L1 TPS >=50%. In the. broader PD--L1 TPS >=1% population, the ORR was 70.8% and DCR was 91.7%.Monotherapy efficacy in Immunotherapy -pretreated NSCLC and IO-nonresponsive \"cold tumors\" further validates CTLA-4 activity and efficacy.-- In second-line NSCLC patients (all previously treated with IO plus. -- In patients with heavily pretreated metastatic colorectal cancer ,CS2009 monotherap","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0347712357.USD","BK4211","IND","BK4567","GDXJ","LU1093756325.SGD","ORR","CDE","LU0053666078.USD","LU1093756168.USD","LU1721428933.USD","LU2413666426.HKD","LU1223082196.USD","SGDM","BK4121","IE00BFXG0V08.USD","SIL","XME","02616","BK4195","PFS","BK4588","LU2211817866.USD","LU1223083913.SGD","BK4107","IE00B5TLWC47.USD","BK4017","BK4548","BK1574","BK4585","L","LU1223082519.USD","LU2413666699.HKD","IE00BYQQ9H92.USD","LU2487616109.SGD","LU0210528500.USD","BK1161","BK4533","MTD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662955085","title":"Press Release: CStone 2026 Interim Results: Accelerating Pipeline 2.0 Execution and Sustained Global Commercial Momentum","url":"https://stock-news.laohu8.com/highlight/detail?id=2662955085","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662955085?lang=en_us&edition=fundamental","pubTime":"2026-08-27 22:15","pubTimestamp":1787840100,"startTime":"0","endTime":"0","summary":"CS2009 Achieved Key Clinical Validations for Efficacy and SafetyAs of August 2026, updated data further confirmed the favorable safety profile of CS2009 and demonstrated strengthened efficacy across multiple key cohorts compared with the data presented at ASCO in May 2026. With expanded patient enrollment and longer follow-up, improvements were observed in both the objective response rate  and duration of response :Compelling monotherapy efficacy in first-line non-small cell lung cancer -- At the 30 mg/kg dose level, CS2009 achieved an ORR of 100% and a disease. control rate  of 100% in patients with PD-L1 TPS >=50%. In the. broader PD--L1 TPS >=1% population, the ORR was 70.8% and DCR was 91.7%.Monotherapy efficacy in Immunotherapy -pretreated NSCLC and IO-nonresponsive \"cold tumors\" further validates CTLA-4 activity and efficacy-- In second-line NSCLC patients (all previously treated with IO plus. -- In patients with heavily pretreated metastatic colorectal cancer ,CS2009 monotherapy","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU2413666699.HKD","SIL","XME","PFS","ORR","LU2413666426.HKD","BK1161","L","SGDM","BK4211","BK4533","LU1223083913.SGD","LU0347712357.USD","BK4121","LU1093756168.USD","GDXJ","CDE","LU1093756325.SGD","LU0053666078.USD","BK4107","BK4017","IND","BK1574","BK4585","IE00BYQQ9H92.USD","IE00BFXG0V08.USD","02616","LU1223082519.USD","LU2487616109.SGD","BK4195","BK4548","BK4588","MTD","LU0210528500.USD","IE00B5TLWC47.USD","LU2211817866.USD","LU1223082196.USD","LU1721428933.USD","BK4567"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2662085166","title":"Press Release: Harbour BioMed Reports 2026 Interim Results: Three Integrated Growth Engines Accelerate Execution of Its Platform-Based Strategy","url":"https://stock-news.laohu8.com/highlight/detail?id=2662085166","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2662085166?lang=en_us&edition=fundamental","pubTime":"2026-08-27 22:05","pubTimestamp":1787839500,"startTime":"0","endTime":"0","summary":"established out-licensing agreements for innovative products, and strong. -- Profit for the period reached US$64.9 million, and adjusted net profit. for the period[1] was approximately US$71.6 million, marking seven","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4022","BK1574","BK1583","MSS","02142","ORR","AAQC","BK4113","R","BK4135","CNS","BK1161","BK4232"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":33,"pageCount":1,"totalSize":130,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/ORR\",params:#limit:6,delay:false,,,undefined,":[]}}